OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lynch, T. J., Jr. [1 ]
Neal, J. [2 ]
Bondarenko, I. [3 ]
Luft, A. [4 ]
Serwatowski, P. [5 ]
Barlesi, F. [9 ]
Chacko, R. [10 ]
Sebastian, M. [6 ]
Cuillerot, J. [7 ]
Reck, M. [8 ]
机构：
[1] Yale Univ, Ctr Canc, New Haven, CT USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Dnipropetrovsk Municipal Clin Hosp 4, Dept Oncol Radiodiagnosis & Radioth, Dnepropetrovsk, Ukraine
[4] Leningrad Reg Clin Hosp, State Inst, St Petersburg, Russia
[5] Oddzial Chemioterapii, Szczecin, Poland
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA
[8] Hosp Grosshansdorf, Grosshansdorf, Germany
[9] Univ Mediterranee Assistance Publ Hapitaux Marsei, Marseille, France
[10] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [21] Update of a phase I/II trial of carboplatin/gemcitabine plus escalating doses of celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).
    Burton, JD
    Badine, E
    El-Sayah, D
    Dib, E
    Forte, F
    Terjanian, T
    Odaimi, M
    Vesoniaraki, M
    Friscia, P
    Lowry, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 700S - 700S
  • [22] First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
    Zhou, C.
    Cheng, Y.
    Chen, J.
    Xu, X.
    Chen, G.
    Pan, Y.
    Fang, Y.
    Wang, Q.
    Huang, Y.
    Yao, W.
    Wang, R.
    Li, X.
    Zhang, W.
    Zhang, Y.
    Shi, J.
    Cao, P.
    Wang, D.
    Lv, D.
    Luo, H.
    Yang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S28 - S28
  • [23] A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Socinski, M. A.
    Saleh, M. N.
    Trent, D. F.
    Dobbs, T. W.
    Zehngebot, L. M.
    Levine, M. A.
    Bordoni, R.
    Stella, P. J.
    ANNALS OF ONCOLOGY, 2009, 20 (06) : 1068 - 1073
  • [24] Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)
    Ansari, R. H.
    Gonin, R.
    Socinski, M.
    Edelman, M.
    Catalano, R.
    Marinucci, D.
    Comis, R.
    Obasaju, C.
    Treat, J. A.
    Belani, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC)
    Li, Mingjia
    Zhao, Songzhu
    Chian, Kenneth
    Kwon, Hyunwoo
    Jones, Nicholas
    Khorasanchi, Adam
    Gauntner, Timothy
    Coss, Christopher C.
    Phelps, Mitch A.
    Spakowicz, Daniel
    Wei, Lai
    Alahmadi, Asrar
    Memmott, Regan Michelle
    Kaufman, Jacob
    He, Kai
    Shields, Peter G.
    Carbone, David Paul
    Otterson, Gregory Alan
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
    Yamamoto, N.
    Sato, Y.
    Tamura, T.
    Kunitoh, H.
    Ohe, Y.
    Katori, N.
    Sawada, J.
    Sekine, A.
    Nakamura, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] DYNAMIC PREDICTION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN NON-SMALL CELL LUNG CANCER (NSCLC) USING TUMOR SIZE: A LONGITUDINAL JOINT MODELING APPROACH.
    Al-Huniti, N.
    Onishchenko, D.
    Xu, H.
    Zhou, D.
    Masson, E.
    Helmlinger, G.
    Tomkinson, H.
    Abdallah, K.
    Dunyak, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S55 - S55
  • [28] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [29] PLATINUM BASED CHEMOTHERAPY IN STAGE IIIB AND IV NON-SMALL CELL LUNG CANCER (NSCLC) - THE EFFECT ON SURVIVAL
    Mobarek, N. A.
    LUNG CANCER, 2009, 64 : S57 - S57
  • [30] Preliminary results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) plus Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Kocs, D. M.
    Raju, R. N.
    Socinski, M. A.
    Stinchcombe, T. E.
    Rousey, S. R.
    Barrera, D.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Obasaju, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345